Glial growth factor 2 promotes functional recovery with treatment initiated up to 7 days after permanent focal ischemic stroke

Neuropharmacology

Volumn 59, Issue 7-8, 2010, Pages 640-649

  Iaci, Jennifer F ^a   Ganguly, Anindita ^a   Finklestein, Seth P ^b   Parry, Tom J ^a   Ren, JingMei ^b   Saha, Subhash ^a   Sietsma, Dana K ^b   Srinivas, Maya ^a   Vecchione, Andrea M ^a   Caggiano, Anthony O ^a  

^a ACORDA THERAPEUTICS INC   (United States)

^b Biotrofix Inc   (United States)

Author keywords

GGF2; Ischemia; MCAO; Neuregulin; Recovery

Indexed keywords

NEU DIFFERENTIATION FACTOR; NEURITE PROMOTING FACTOR 2; NEUROTROPHIC FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY EQUILIBRIUM; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; CONVALESCENCE; DRUG EFFECT; DRUG EFFICACY; EARLY INTERVENTION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; RAT; SENSORIMOTOR FUNCTION; THERAPY DELAY;

ANIMALS; BRAIN; BRAIN INFARCTION; EPIDERMAL GROWTH FACTOR; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; NEUREGULIN-1; NEUROPROTECTIVE AGENTS; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; STROKE; TIME FACTORS;

EID: 77958082505     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.07.017     Document Type: Article

References (58)

1. Biernaskie J., Corbett D. Enriched rehabilitative training promotes improved forelimb motor function and enhanced dendritic growth after focal ischemic injury. J. Neurosci. 2001, 21:5272-5280.
2. Borlongan C.V., Sanberg P.R. Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. J. Neurosci. 1995, 15:5372-5378.
3. Buonanno A., Fischbach G.D. Neuregulin and ErbB receptor signaling pathways in the nervous system. Curr. Opin. Neurobiol. 2001, 11:287-296.
4. Buonanno A., Kwon O.B., Yan L., Gonzalez C., Longart M., Hoffman D., Vullhorst D. Neuregulins and neuronal plasticity: possible relevance in schizophrenia. Novartis Found. Symp. 2008, 289:165-177. discussion 177-169, 193-165.
5. Carmichael S.T. Gene expression changes after focal stroke, traumatic brain and spinal cord injuries. Curr. Opin. Neurol. 2003, 16:699-704.
6. Carraway K.L., Burden S.J. Neuregulins and their receptors. Curr. Opin. Neurobiol. 1995, 5:606-612.
7. Chen Y.J., Zhang M., Wang P., Zhu X.H., Gao T.M. Nan Fang Yi Ke Da Xue Xue Bao 2008, 28:1771-1774.
8. Cheng Y.D., Al-Khoury L., Zivin J.A. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004, 1:36-45.
9. Comelli M.C., Guidolin D., Seren M.S., Zanoni R., Canella R., Rubini R., Manev H. Time course, localization and pharmacological modulation of immediate early inducible genes, brain-derived neurotrophic factor and trkB messenger RNAs in the rat brain following photochemical stroke. Neuroscience 1993, 55:473-490.
10. Cramer S.C. Repairing the human brain after stroke: I. Mechanisms of spontaneous recovery. Ann. Neurol. 2008, 63:272-287.
11. Cramer S.C. Repairing the human brain after stroke. II. Restorative therapies. Ann. Neurol. 2008, 63:549-560.
12. Crovello C.S., Lai C., Cantley L.C., Carraway K.L. Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2. J. Biol. Chem. 1998, 273:26954-26961.
13. De Ryck M., Van Reempts J., Duytschaever H., Van Deuren B., Clincke G. Neocortical localization of tactile/proprioceptive limb placing reactions in the rat. Brain Res. 1992, 573:44-60.
14. Devine J.M., Zafonte R.D. Physical exercise and cognitive recovery in acquired brain injury: a review of the literature. PM R 2009, 1:560-575.
15. Di Segni A., Shaharabani E., Stein R., Pinkas-Kramarski R. Neuregulins rescue PC12-ErbB-4 cells from cell death induced by beta-amyloid peptide: involvement of PI3K and PKC. J. Mol. Neurosci. 2005, 26:57-69.
16. Dimayuga F.O., Ding Q., Keller J.N., Marchionni M.A., Seroogy K.B., Bruce-Keller A.J. The neuregulin GGF2 attenuates free radical release from activated microglial cells. J. Neuroimmunol. 2003, 136:67-74.
17. Finklestein S.P., Caday C.G., Kano M., Berlove D.J., Hsu C.Y., Moskowitz M., Klagsbrun M. Growth factor expression after stroke. Stroke 1990, 21:III122-III124.
18. Fischbach G.D. NRG1 and synaptic function in the CNS. Neuron 2007, 54:495-497.
19. Flores A.I., Mallon B.S., Matsui T., Ogawa W., Rosenzweig A., Okamoto T., Macklin W.B. Akt-mediated survival of oligodendrocytes induced by neuregulins. J. Neurosci. 2000, 20:7622-7630.
20. Foley N.C., Teasell R.W., Bhogal S.K., Doherty T., Speechley M.R. The efficacy of stroke rehabilitation: a qualitative review. Top. Stroke Rehabil. 2003, 10:1-18.
21. Furlan A.J., Katzan I.L., Caplan L.R. Thrombolytic therapy in acute ischemic stroke. Curr. Treat. Options Cardiovasc. Med. 2003, 5:171-180.
22. Heiss W.D., Grond M., Thiel A., von Stockhausen H.M., Rudolf J., Ghaemi M., Lottgen J., Stenzel C., Pawlik G. Tissue at risk of infarction rescued by early reperfusion: a positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke. J. Cereb. Blood Flow Metab. 1998, 18:1298-1307.
23. Johansson B.B. Brain plasticity and stroke rehabilitation. The Willis lecture. Stroke 2000, 31:223-230.
24. Katzan I.L., Furlan A.J., Lloyd L.E., Frank J.I., Harper D.L., Hinchey J.A., Hammel J.P., Qu A., Sila C.A. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000, 283:1151-1158.
25. Komjati K., Mabley J.G., Virag L., Southan G.J., Salzman A.L., Szabo C. Poly(ADP-ribose) polymerase inhibition protect neurons and the white matter and regulates the translocation of apoptosis-inducing factor in stroke. Int. J. Mol. Med. 2004, 13:373-382.
26. Kwon O.B., Paredes D., Gonzalez C.M., Neddens J., Hernandez L., Vullhorst D., Buonanno A. Neuregulin-1 regulates LTP at CA1 hippocampal synapses through activation of dopamine D4 receptors. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:15587-15592.
27. Lemke G. Neuregulin-1 and myelination. Sci. STKE 2006, 2006:pe11.
28. Li B., Woo R.S., Mei L., Malinow R. The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. Neuron 2007, 54:583-597.
29. Li Q., Stephenson D. Postischemic administration of basic fibroblast growth factor improves sensorimotor function and reduces infarct size following permanent focal cerebral ischemia in the rat. Exp. Neurol. 2002, 177:531-537.
30. Li Y., Xu Z., Ford G.D., Croslan D.R., Cairobe T., Li Z., Ford B.D. Neuroprotection by neuregulin-1 in a rat model of permanent focal cerebral ischemia. Brain Res. 2007, 1184:277-283.
31. Lloyd-Jones D., Adams R., Carnethon M., De Simone G., Ferguson T.B., Flegal K., Ford E., Furie K., Go A., Greenlund K., Haase N., Hailpern S., Ho M., Howard V., Kissela B., Kittner S., Lackland D., Lisabeth L., Marelli A., McDermott M., Meigs J., Mozaffarian D., Nichol G., O'Donnell C., Roger V., Rosamond W., Sacco R., Sorlie P., Stafford R., Steinberger J., Thom T., Wasserthiel-Smoller S., Wong N., Wylie-Rosett J., Hong Y. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:e21-e181.
32. Lo A.C., Guarino P.D., Richards L.G., Haselkorn J.K., Wittenberg G.F., Federman D.G., Ringer R.J., Wagner T.H., Krebs H.I., Volpe B.T., Bever C.T., Bravata D.M., Duncan P.W., Corn B.H., Maffucci A.D., Nadeau S.E., Conroy S.S., Powell J.M., Huang G.D., Peduzzi P. Robot-assisted therapy for long-term upper-limb impairment after stroke. N. Engl. J. Med. 2010, 362:1772-1783.
33. Loeb J.A. Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosis. Neurology 2007, 68:S38-S42. discussion S43-S54.
34. Mauler F., Horvath E. Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury. J. Cereb. Blood Flow Metab. 2005, 25:451-459.
35. Mei L., Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 2008, 9:437-452.
36. Neddens J., Vullhorst D., Paredes D., Buonanno A. Neuregulin links dopaminergic and glutamatergic neurotransmission to control hippocampal synaptic plasticity. Commun. Integr. Biol. 2009, 2:261-264.
37. NINDS r-PSSG Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 1995, 333:1581-1587.
38. Price C.J., Wang D., Menon D.K., Guadagno J.V., Cleij M., Fryer T., Aigbirhio F., Baron J.C., Warburton E.A. Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. Stroke 2006, 37:1749-1753.
39. Que M., Schiene K., Witte O.W., Zilles K. Widespread up-regulation of N-methyl-D-aspartate receptors after focal photothrombotic lesion in rat brain. Neurosci. Lett. 1999, 273:77-80.
40. Redecker C., Wang W., Fritschy J.M., Witte O.W. Widespread and long-lasting alterations in GABA(A)-receptor subtypes after focal cortical infarcts in rats: mediation by NMDA-dependent processes. J. Cereb. Blood Flow Metab. 2002, 22:1463-1475.
41. Rudd A., Wolfe C. Aetiology and pathology of stroke. Hosp. Pharm. 2002, 9:5.
42. Saver J.L., Albers G.W., Dunn B., Johnston K.C., Fisher M. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke 2009, 40:2594-2600.
43. Saver J.L., Gornbein J., Grotta J., Liebeskind D., Lutsep H., Schwamm L., Scott P., Starkman S. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window: joint outcome table analysis of the ECASS 3 trial. Stroke 2009, 40:2433-2437.
44. Savitz S.I. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp. Neurol. 2007, 205:20-25.
45. Schallert T. Behavioral tests for preclinical intervention assessment. NeuroRx 2006, 3:497-504.
46. Schulz J.B., Weller M., Matthews R.T., Heneka M.T., Groscurth P., Martinou J.C., Lommatzsch J., von Coelln R., Wullner U., Loschmann P.A., Beal M.F., Dichgans J., Klockgether T. Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. Cell Death Differ. 1998, 5:847-857.
47. STAIR Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999, 30:2752-2758.
48. Sun H.S., Doucette T.A., Liu Y., Fang Y., Teves L., Aarts M., Ryan C.L., Bernard P.B., Lau A., Forder J.P., Salter M.W., Wang Y.T., Tasker R.A., Tymianski M. Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. Stroke 2008, 39:2544-2553.
49. Tamura A., Gotoh O., Sano K. No To Shinkei 1986, 38:747-751.
50. Tan K.T., Lip G.Y., Blann A.D. Post-stroke inflammatory response: effects of stroke evolution and outcome. Curr. Atheroscler. Rep. 2003, 5:245-251.
51. Taveggia C., Thaker P., Petrylak A., Caporaso G.L., Toews A., Falls D.L., Einheber S., Salzer J.L. Type III neuregulin-1 promotes oligodendrocyte myelination. Glia 2008, 56:284-293.
52. ter Laak M.P., Hamers F.P., Kirk C.J., Gispen W.H. rhGGF2 protects against cisplatin-induced neuropathy in the rat. J. Neurosci. Res. 2000, 60:237-244.
53. Wahlgren N.G., Lyden P. Neuroprotectants in the treatment of stroke - an overview. J. Stroke Cerebrovasc. Dis. 2000, 9:32-35.
54. Woo R.S., Li X.M., Tao Y., Carpenter-Hyland E., Huang Y.Z., Weber J., Neiswender H., Dong X.P., Wu J., Gassmann M., Lai C., Xiong W.C., Gao T.M., Mei L. Neuregulin-1 enhances depolarization-induced GABA release. Neuron 2007, 54:599-610.
55. Xu Z., Croslan D.R., Harris A.E., Ford G.D., Ford B.D. Extended therapeutic window and functional recovery after intraarterial administration of neuregulin-1 after focal ischemic stroke. J. Cereb. Blood Flow Metab. 2006, 26:527-535.
56. Xu Z., Ford G.D., Croslan D.R., Jiang J., Gates A., Allen R., Ford B.D. Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression. Neurobiol. Dis. 2005, 19:461-470.
57. Xu Z., Jiang J., Ford G., Ford B.D. Neuregulin-1 is neuroprotective and attenuates inflammatory responses induced by ischemic stroke. Biochem. Biophys. Res. Commun. 2004, 322:440-446.
58. Zhang L., Fletcher-Turner A., Marchionni M.A., Apparsundaram S., Lundgren K.H., Yurek D.M., Seroogy K.B. Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures. J. Neurochem. 2004, 91:1358-1368.